Biodesix, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Biodesix, Inc. | BDSX - NASDAQ |
$17.00-$19.00 | $18.00 | $13.59 | 4 million | 10/28/2020 |
| Morgan Stanley, William Blair | ||||||
Co-Manager(s): Canaccord Genuity, BTIG | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-10-02 Terms Added 2020-10-21 | ||||||
Biodesix, Inc. Quote & Chart - Click for current quote - BDSX
IPO Boutique aggregates information on public companies and private companies, such as "BDSX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Biodesix, Inc. (adapted from Biodesix, Inc. prospectus):
They are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "BDSX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.